Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insmed Incorporated - Common Stock (NQ: INSM )

78.10 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21
Open 78.10
Bid (Size) 76.01 (2)
Ask (Size) 82.99 (1)
Prev. Close 78.10
Today's Range 78.10 - 78.10
52wk Range 21.92 - 84.91
Shares Outstanding 115,246,666
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025. 
Via Benzinga
Exposures Product Safety
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga

Performance

YTD
+11.65%
+11.65%
1 Month
+0.61%
+0.61%
3 Month
+2.93%
+2.93%
6 Month
+2.05%
+2.05%
1 Year
+167.19%
+167.19%

More News

Read More
Earnings Scheduled For February 20, 2025
Via Benzinga
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
Via Benzinga
Peering Into Insmed's Recent Short Interest
Via Benzinga
Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
Via Benzinga
How Is The Market Feeling About Insmed?
Via Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert
Via Stocktwits
Topics Government
Exposures Political
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank
Via The Motley Fool
Topics Stocks
Exposures US Equities
How Is The Market Feeling About Insmed?
Via Benzinga
Demystifying Insmed: Insights From 7 Analyst Reviews
Via Benzinga
Insmed's Options: A Look at What the Big Money is Thinking
Via Benzinga
A Glimpse of Insmed's Earnings Potential
Via Benzinga
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today
Via Benzinga
Peering Into Insmed's Recent Short Interest
Via Benzinga
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Via The Motley Fool
Topics Stocks
Exposures US Equities
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Topics Government
Exposures Political
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years
Via Benzinga
(INSM) - Analyzing Insmed's Short Interest
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.